Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes
Edvardas Kaminskas(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Amy B. Baird(Center for Drug Evaluation and Research), Shwu‐Luan Lee(Center for Drug Evaluation and Research), Li-Shan Hsieh(Center for Drug Evaluation and Research), Rajeshwara Sridhara(Center for Drug Evaluation and Research), Atiqur Rahman, Ann Farrell(Center for Drug Evaluation and Research), Hasmukh Patel(Center for Drug Evaluation and Research), John K. Leighton, Sophia Abraham(United States Food and Drug Administration), Yongcheng Wang(United States Food and Drug Administration)
Cited by 424
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k